Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model

Galectin-9 (Gal-9) enhances tumor immunity mediated by T cells, macrophages, and dendritic cells. Its expression level in various cancers correlates with prognosis. Furthermore, Gal-9 directly induces apoptosis in various cancers; however, its mechanism of action and bioactivity has not been clarified. We evaluated Gal-9 antitumor effect against esophageal squamous cell carcinoma (ESCC) to analyze the dynamics of apoptosis-related molecules, elucidate its mechanism of action, and identify relevant changes in miRNA expressions. KYSE-150 and KYSE-180 cells were treated with Gal-9 and their proliferation was evaluated. Gal-9 inhibited cell proliferation in a concentration-dependent manner. The xenograft mouse model established with KYSE-150 cells was administered with Gal-9 and significant suppression in the tumor growth observed. Gal-9 treatment of KYSE-150 cells increased the number of Annexin V-positive cells, activation of caspase-3, and collapse of mitochondrial potential, indicating apoptosis induction. c-Jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38) phosphorylation were activated and could be involved in apoptosis. Therefore, Gal-9 induces mitochondria-mediated apoptosis of ESCC and inhibits cell proliferation in vitro and in vivo with JNK and p38 activation.

[1]  Wei-wei Wang,et al.  miR-582-5p inhibits invasion and migration of salivary adenoid cystic carcinoma cells by targeting FOXC1 , 2017, Japanese journal of clinical oncology.

[2]  T. Niki,et al.  Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. , 2017, Oncology reports.

[3]  Li Wang,et al.  A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. , 2017, International journal of surgery.

[4]  Ken Kato,et al.  Chemoradiotherapy for esophageal squamous cell cancer. , 2016, Japanese journal of clinical oncology.

[5]  S. Dhar,et al.  Nanotechnology inspired tools for mitochondrial dysfunction related diseases. , 2016, Advanced drug delivery reviews.

[6]  T. Niki,et al.  Galectin-9: An anticancer molecule for gallbladder carcinoma. , 2016, International journal of oncology.

[7]  Ahmedin Jemal,et al.  Global Cancer Incidence and Mortality Rates and Trends—An Update , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[8]  T. Niki,et al.  Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. , 2015, Oncology reports.

[9]  P. Stephens,et al.  Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. , 2015, The oncologist.

[10]  X Zhang,et al.  Upregulation of miR-582-5p inhibits cell proliferation, cell cycle progression and invasion by targeting Rab27a in human colorectal carcinoma , 2015, Cancer Gene Therapy.

[11]  M. Napimoga,et al.  Galectin-9 as an important marker in the differential diagnosis between oral squamous cell carcinoma, oral leukoplakia and oral lichen planus. , 2015, Immunobiology.

[12]  T. Niki,et al.  Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. , 2015, International journal of oncology.

[13]  Q. Ye,et al.  miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3 , 2015, Tumor Biology.

[14]  A. Griffioen,et al.  Galectin expression in cancer diagnosis and prognosis: A systematic review. , 2015, Biochimica et biophysica acta.

[15]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[16]  T. Masaki,et al.  miRNA in hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  Yin-Ji Li,et al.  Regulation of osteoclastogenesis through Tim-3: possible involvement of the Tim-3/galectin-9 system in the modulation of inflammatory bone destruction , 2014, Laboratory Investigation.

[18]  Siew Wui Chan,et al.  Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[19]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[20]  T. Niki,et al.  Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies , 2014, The Journal of experimental medicine.

[21]  C. Decaestecker,et al.  Galectin fingerprinting in naso-sinusal diseases , 2014, Oncology reports.

[22]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[23]  N. Kosaka,et al.  Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  T. Niki,et al.  The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells , 2012, The Journal of investigative dermatology.

[25]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[26]  M. Taniwaki,et al.  Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia , 2010, Molecular Cancer Research.

[27]  Jessica A. Randall,et al.  Correction: A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PLoS ONE.

[28]  M. Taniwaki,et al.  Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways , 2010, Leukemia.

[29]  Jessica A. Randall,et al.  A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PloS one.

[30]  T. Niki,et al.  Galectin-9 Is a High Affinity IgE-binding Lectin with Anti-allergic Effect by Blocking IgE-Antigen Complex Formation , 2009, The Journal of Biological Chemistry.

[31]  T. Niki,et al.  Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions1 , 2008, The Journal of Immunology.

[32]  D. Dhanasekaran,et al.  JNK signaling in apoptosis , 2008, Oncogene.

[33]  B. Levine,et al.  Dual Role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation , 2008, Autophagy.

[34]  W. Chow,et al.  Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. , 2008, Journal of the National Cancer Institute.

[35]  T. Niki,et al.  Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. , 2008, Clinical immunology.

[36]  A. Yamauchi,et al.  Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[37]  J. Hirabayashi,et al.  Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family. , 2007, Glycobiology.

[38]  Azad Bonni,et al.  p38 MAP Kinase Mediates Apoptosis through Phosphorylation of BimEL at Ser-65* , 2006, Journal of Biological Chemistry.

[39]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[41]  Phillip D. Zamore,et al.  Ribo-gnome: The Big World of Small RNAs , 2005, Science.

[42]  M. Hirashima,et al.  Development of highly stable galectins: Truncation of the linker peptide confers protease‐resistance on tandem‐repeat type galectins , 2005, FEBS letters.

[43]  M. J. Abedin,et al.  Galectin-9 Induces Apoptosis Through the Calcium-Calpain-Caspase-1 Pathway1 , 2003, The Journal of Immunology.

[44]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[45]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[46]  M. Hirashima,et al.  Human Ecalectin, a Variant of Human Galectin-9, Is a Novel Eosinophil Chemoattractant Produced by T Lymphocytes* , 1998, The Journal of Biological Chemistry.

[47]  H. Handoko,et al.  The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells , 2012 .

[48]  永原 慶子 Galectin-9 increases Tim-3[+] dendritic cells and CD8[+] T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions , 2009 .

[49]  A. Yamauchi,et al.  Galectin-9 in physiological and pathological conditions , 2004, Glycoconjugate Journal.

[50]  S. Srinivasula,et al.  The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity , 2002, Cell Death and Differentiation.